

## Chronic obstructive pulmonary disease (COPD) Committee meeting

**Date:** 03/05/19

**Location:** London

**Minutes:** Approved

<b>Committee members present:</b>	
Andrew Molyneux (Chair)	Present for items 1–6
Lauren Hogg	Present for items 1–6
Nick Hopkinson	Present for items 1–6
Karen O’Hara	Present for items 1–6
Tony Perkins	Present for items 1–6
Louise Restrick	Present for items 1–6
Ravijyot Saggi	Present for items 1–6
Karen Sennett	Present for items 1–6
Alan Thomas	Present for items 1–3

<b>In attendance:</b>	
Joe Crutwell Technical Analyst	Present for items 1–6
Rupert Franklin Guideline Commissioning Manager	Present for items 1–6
James Hall Medical Editor	Present for items 1–6
Marie Harrisingh Technical Adviser	Present for items 1–6
Gabriel Rogers Technical Adviser (Health Economics)	Present for items 1- 3

**Observing:** none

<b>Apologies:</b>	
Katy Beckford	Committee member
Sarah MacFadyen	Committee member
Anneka Patel	NICE Project manager

## Committee minutes – COPD meeting 12

Luisa Pettigrew	Committee member
Susan Spiers	NICE Associate Director

### 1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the post consultation meeting on chronic obstructive pulmonary disease (COPD).

The Chair informed the committee of apologies as listed above.

The Chair asked everyone to verbally declare any new interests arising since the last meeting. The following declarations were made:

Committee member	Declaration	Classification	Chairs action
Karen O'Hara, lay member	Patient representative at Mereo Astraeus European Investigator Meeting. No honorarium, expenses only. 17 <sup>th</sup> January 2019	Direct, financial (expenses only)	Declare and participate
Karen O'Hara, lay member	ERN-LUNG Board Meeting. No honorarium, expenses only. 13 <sup>th</sup> -14 <sup>th</sup> March 2019	Direct, financial (expenses only)	Declare and participate
Karen O'Hara, lay member	Baywater Patient Liaison Committee. No honorarium, expenses only – discussion the patient perspective of oxygen supply. 19 <sup>th</sup> March 2019	Direct, financial (expenses only)	Declare and participate
Karen O'Hara, lay member	Alpha-1 Gobar International Congress – chair/moderator for Physicians Education & Collaborative Efforts session. No honorarium, expenses only. 3 <sup>rd</sup> - 6 <sup>th</sup> April 2019	Direct, financial (expenses only)	Declare and participate
Karen O'Hara, lay member	The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency, published January 2019, named as co-author as a member of the Steering Committee.	Direct, non-financial professional and personal	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared previously did not prevent the attendees from fully participating in the meeting.

## Committee minutes – COPD meeting 12

It was noted that the objectives of this meeting were to discuss the stakeholder consultation comments for triple therapy and corticosteroids in relation to COPD. This additional work will publish as an addendum to the updated guideline in June 2019.

### **2. Stakeholder consultation comments and committee discussion**

- **Corticosteroids**

Marie Harrisingh (Technical Adviser) and Joe Crutwell (Technical Analyst) presented consultation comments on the area and the committee discussed against the draft recommendations previously made.

The committee agreed the responses to the stakeholder comments and any necessary changes to the guideline / recommendations.

### **3. Stakeholder consultation comments and committee discussion**

**In people with stable COPD, what is the clinical and cost effectiveness of a LAMA plus a LABA plus ICS compared with:**

- a LABA plus an inhaled corticosteroid (ICS)
- a LAMA plus LABA

Marie Harrisingh (Technical Adviser) and Joe Crutwell (Technical Analyst) presented consultation comments on the area and the committee discussed against the draft recommendations previously made.

The committee agreed the responses to the stakeholder comments and any necessary changes to the guideline / recommendations/ algorithm.

### **4. MHRA alert**

Marie Harrisingh (Technical Adviser) informed the committee that there was a MHRA alert that was relevant for the related guideline (Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing NG144) and that NG144 would be amended to take this into account.

### **5. Summary of meeting and next steps**

Marie Harrisingh, Technical adviser, gave a summary of the meeting and next steps.

### **6. AOB**

No other business was discussed.